title: Effectiveness of a novel biodegradable polymer, sirolimus-eluting stent platform in percutaneous coronary intervention.
abstract: BACKGROUND
  The purpose of this registry is to report the immediate and long-term safety and efficacy of the Biotronik Orsiro stent in an unselected population during everyday practice.
  
  
  METHODS
  Between May 2012 and June 2013, 246 consecutive coronary angioplasty procedures were performed using at least one Orsiro drug-eluting stent, in 225 patients and 303 lesions.
  
  
  RESULTS
  Diabetes was present in 34.7% of patients. Procedures were non-elective percutaneous coronary intervention (PCI) in 17.1% of cases and acute coronary syndromes were 55.1%. Radial vascular access was used in 78% of cases, multivessel PCI was performed in 19.5% of the procedures. In 81.6% of cases lesions were B2/C type, 20.7% of procedures had bifurcation lesions. Procedural success was 99.6%. No acute thrombosis occurred. Clinical follow-up median period was 24.3 (±8.28) months and FU was available in 93.7% of patients. Death for any cause occurred in 11 patients (5.2%), 6 of them were non cardiac-related. Cardiac-related death rate was 2.4%. Two patients had in-stent restenosis. The overall target lesion failure rate was 3.3%.
  
  
  CONCLUSIONS
  This observational data regards our experience with Biotronik Orsiro stent in an unselected population. This initial data, although limited by a mainly clinical follow-up and restricted number of patients, confirms the good clinical performance of this sirolimus-eluting stent with a biodegradable polymer in everyday practice, including complex lesions, according to current larger studies in the literature.
authors.affiliation: Interventional Cardiology Unit, S. Maria University Hospital, Terni, Italy - enricoboschetti@virgilio.it.
authors.forename: Marcello
authors.initials: M
authors.lastname: Dominici
authors.forename: Alessio
authors.initials: A
authors.lastname: Arrivi
authors.forename: Marco
authors.initials: M
authors.lastname: Bazzucchi
authors.forename: Marcella
authors.initials: M
authors.lastname: De Paolis
authors.forename: Caterina
authors.initials: C
authors.lastname: Milici
authors.forename: Carlo
authors.initials: C
authors.lastname: Bock
authors.forename: Attilio
authors.initials: A
authors.lastname: Placanica
authors.forename: Ludovico
authors.initials: L
authors.lastname: Lazzari
authors.forename: Roberto
authors.initials: R
authors.lastname: Diletti
authors.forename: Enrico
authors.initials: E
authors.lastname: Boschetti
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011108:Polymers / Q000737:chemistry; D011474:Prosthesis Design; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D011108:Polymers; D020123:Sirolimus